The topline results from RASolute-302 have had the oncology world abuzz since.
https://cancerletter.com/clinical/20260605_1/
Ozgur Sahin named to co-lead Cancer Biology & Immunology program at MUSC Hollings
https://cancerletter.com/in-brief/20260612_7a/
Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
https://cancerletter.com/the-cancer-letter/20260612_1/
Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with an emergent ESR1 tumor mutation, phase III SERENA-6 trial finds
https://cancerletter.com/clinical-roundup/20260605_9d/
As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded
https://cancerletter.com/the-cancer-letter/20260612_3/
NIH calls for comment on proposal to limit the number of RPGs per PI
https://cancerletter.com/cancer-policy/20260612_6a/
Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy. Guest editorial by Peter Garrett.
https://cancerletter.com/trials-and-tribulations/20260612_4/
Survivorship begins at diagnosis—cancer care system must recognize this. Guest editorial by Saro Armenian, DO, MPH.
@cityofhope.bsky.social
https://cancerletter.com/sponsored-article/20260612_5/
"By unleashing hope for pancreatic cancer, we can attest that there is hope for all cancers," Rathmell writes.
https://cancerletter.com/trials-and-tribulations/20260605_2/
House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget
https://cancerletter.com/capitol-hill/20260612_2/
Dear Colleagues, Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own. We […]
In 1989, I stood in front of the AIDS Memorial Quilt on a hot summer afternoon on the National Mall in Washington DC. I was 28 years old and living with the man who I have been with ever since. I was still finding my place in the gay community and, like many people visiting […]
Last week, Wafik El-Deiry, a cancer researcher at Brown University, showed up at a Senate hearing to talk about what he sees as dangers of the COVID-19 vaccine. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all […]
cancerletter.com
Here are the battle lines: The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight. […]
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment. To access this subscriber-only content please log in or […]
Ozgur Sahin was named co-leader of the Cancer Biology & Immunology Program at MUSC Hollings Cancer Center. Sahin joins Sophie Paczesny in that role. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
cancerletter.com
NIH has published a request for information on its proposed policy that would cap the number of research project grants, or RPGs, for which an individual can simultaneously serve as principal investigator or multi-principal investigator. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login […]
The oncology field is confronting three forces simultaneously: A rapidly growing population of long-term survivors, More patients living with advanced cancers once deemed incurable, and The rise of early-onset cancers. These trends demand a paradigm shift. Survivorship is no longer a peripheral phase of care; it is a central and defining component of modern oncology. […]
A note for historians: On April 21, 2026, pancreatic cancer finally began to budge. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
